TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00494416

Intervention type: OTHER
Group type: OTHER
Intervention: delivery approaches of malaria intermittent preventive treatment in pregnancy
Description: Health centre based delivery approach (PHC). IPT/SP will be delivered to pregnant women presenting to the health centre for ANC visit.~Joint with advanced strategies delivery approach (JAS). In addition to passive delivery at health centres, the pregnant women will be reached during preventive activities the health staff carry out regularly in villages Community based distribution delivery approach (CBD). In addition to passive delivery at health centres, the pregnant women will be reached by traditional birth attendants (TBAs) or representatives of village women's associations (RWAs).

Intervention type: OTHER
Group type: OTHER
Intervention: delivery approaches of malaria intermittent preventive treatment in pregnancy
Description: Health centre based delivery approach (PHC). IPT/SP will be delivered to pregnant women presenting to the health centre for ANC visit.~Joint with advanced strategies delivery approach (JAS). In addition to passive delivery at health centres, the pregnant women will be reached during preventive activities the health staff carry out regularly in villages Community based distribution delivery approach (CBD). In addition to passive delivery at health centres, the pregnant women will be reached by traditional birth attendants (TBAs) or representatives of village women's associations (RWAs).
Study: NCT04332991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine is available in 200 mg oral tablets of hydroxychloroquine sulfate.~For this COVID-19 trial, we will use an oral or enteral dose of hydroxychloroquine 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.
Study: NCT01684345

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 1 gevokizumab
Description: Solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 2 gevokizumab
Description: Solution for subcutaneous injection
Study: NCT02246647

Intervention type: DIAGNOSTIC_TEST
Intervention: Permeability measurement
Description: Saccharide excretion was compared between IBS-C and healthy volunteers

Intervention type: DIAGNOSTIC_TEST
Intervention: Permeability measurement
Description: Saccharide excretion was compared between IBS-C and healthy volunteers

Intervention type: PROCEDURE
Intervention: Esophagogastroduodenoscopy
Description: Duodenal biopsies were collected from IBS-C and healthy volunteers

Intervention type: PROCEDURE
Intervention: Esophagogastroduodenoscopy
Description: Duodenal biopsies were collected from IBS-C and healthy volunteers

Intervention type: PROCEDURE
Intervention: Flexible sigmoidoscopy
Description: Colonic biopsies were collected from IBS-C and healthy volunteers

Intervention type: PROCEDURE
Intervention: Flexible sigmoidoscopy
Description: Colonic biopsies were collected from IBS-C and healthy volunteers
Study: NCT03889327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological Feedback & Psychoeducation (Cognition)
Description: The customary practice of providing feedback on neuropsychological test performance can address patient misperceptions of cognitive impairment by distinguishing between perceived and objective neuropsychological test performance. Explaining how normative data is derived by comparison to same age peers, patients are able to better understand their current cognitive functioning. The proposed intervention will employ both psychoeducation and neuropsychological feedback for participants assigned to the treatment group, and psychoeducation for participants assigned to the control group. Both groups will watch 3 brief videos (exactly the same length in time) and answer two qualitative questions following each video.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation (Health)
Description: Information on importance of healthy eating habits and benefits of a healthy diet including medical outcomes such as reduced blood pressure, and decreased risk of stroke and cardiovascular disease. This intervention will also cover recommended serving sizes for daily helpings of fruits and vegetables, and ways to incorporate fruits and vegetables into meals throughout the day. The control intervention will include expert testimony from a nutritionist and expert dietician.
Study: NCT03854903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is taken orally.
Study: NCT02325752

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: A multidisciplinary team delivered the transitional care program.~Our transitional care program focused on four key areas:~1. Post discharge surveillance of the patient to ensure adherence to care plans.~2. Coordination of follow-up visits with specialist care providers.~3. Patent education and care giver training.~4. Activation of community and social services.~Upon recruitment, the patients were interviewed and assessed by the team nurse prior to their discharge. Intervention starts upon discharge from the hospital. The duration of the intervention program was 3 months. A follow-up by telephone was made within 72 hours after discharge to assess patient's condition and adherence to treatment plan. Home visits were made within 2 weeks after discharge.
Study: NCT01852851

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Employment and Arthritis: Making it Work
Description: A ten week on-line eLearning program designed to help people with inflammatory arthritis stay employed. The program consists of 1) 5 interactive web-based eLearning modules that participants will complete individually in between the weekly group sessions, 2) 5 weekly group sessions conducted as virtual real-time web-based group meetings led by a trained facilitator, 3) asynchronous communications such as a message board to facilitate additional interactions among participants, 4) consultations with an occupational therapist (in-person)for an ergonomic assessment, and a vocational rehabilitation counsellor (on-line consultation using web technology) for job retention vocational counselling.
Study: NCT01678586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin is a commonly prescribed drug used to treat neuropathic pain.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Gabapentin
Description: Benadryl or diphenhydramine is used as a placebo as it could mimic some common side effects of gabapentin (i.e. sedation, drowsiness, lightheadedness)
Study: NCT03526549

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CCH-aaes
Description: Administered to participants who qualified for, and opted for, retreatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: No treatment administered during 180 days of observation.

Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: No treatment administered during 180 days of observation.
Study: NCT02748096

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient Specific Instrumentation
Description: Patients will undergo a medial unicompartmental knee replacement. This knee replacement is implanted using patient specific cutting guides that have been produced based on the patient's individual anatomy (using plans from pre-operative MRI scans of the patient's knee).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Instrumentation
Description: Patients will undergo a medial unicompartmental knee replacement using standard conventional instruments.
Study: NCT02182076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBF 1120
Description: 150 mg of BIBF 1120 ES soft gelatine capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: 150 mg of BIBF 1120 ES soft gelatine capsules
Study: NCT02648646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otago Exercise Programme and Walk with Ease
Description: The Otago Exercise Programme is a falls prevention program that is successful at reducing falls in adults 65+ years of age. Briefly, this program includes flexibility, progressive lower extremity strengthening with ankle weights, and balance exercises. The investigators are replacing the Otago walking program with the evidence-based Arthritis Foundation's Walk With Ease program.
Study: NCT00869362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes management team
Description: MD evaluation followed by NP education and and medication titration
Study: NCT03772210

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Current will be administered to subject groups as specified in arm descriptions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Current will be administered to subject groups as specified in arm descriptions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Current will be administered to subject groups as specified in arm descriptions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Current will be administered to subject groups as specified in arm descriptions.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Apparent Stimulation administered

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Apparent Stimulation administered

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Apparent Stimulation administered
Study: NCT02253849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study: NCT01545375

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189242A
Description: 4 doses administered intramuscularly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 doses administered intramuscularly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Prevnar 13®
Description: 4 doses administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13®
Description: 4 doses administered intramuscularly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PedvaxHIB®
Description: 4 doses administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PedvaxHIB®
Description: 4 doses administered intramuscularly
Study: NCT01407627

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fructose
Description: Subjects will be randomized to one of 2 sequences:~Sequence 1: Fructose (intervention) 200g daily x 14d followed by Dextrose (control) 200g daily x 14d Sequence 2: Dextrose (control) 200g daily x 14d followed by Fructose (intervention) 200g daily x 14d

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Subjects will be randomized to one of 2 sequences:~Sequence 1: Fructose (intervention) 200g daily x 14d followed by Dextrose (control) 200g daily x 14d Sequence 2: Dextrose (control) 200g daily x 14d followed by Fructose (intervention) 200g daily x 14d
Study: NCT00939861

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy
Description: colorectal resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparotomy
Description: colorectal resection
Study: NCT03053102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Danicopan was administered as multiple oral doses over a period of at least 28 days.
Study: NCT02014909

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KTN3379
Description: Single agent KTN3379 or in combination administered until unacceptable toxicity or progressive disease

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KTN3379
Description: Single agent KTN3379 or in combination administered until unacceptable toxicity or progressive disease

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KTN3379
Description: Single agent KTN3379 or in combination administered until unacceptable toxicity or progressive disease

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KTN3379
Description: Single agent KTN3379 or in combination administered until unacceptable toxicity or progressive disease

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KTN3379
Description: Single agent KTN3379 or in combination administered until unacceptable toxicity or progressive disease
Study: NCT01754805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: oral
Study: NCT03958045

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Rucaparib and Nivolumab
Description: Rucaparib (600mg BID) and Nivolumab (480mg IV q4 wk)
Study: NCT00905437

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as an adjunct to standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: 75 mg BD for 14 days
Study: NCT03799445

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02120690

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Trigeminal nerve stimulation
Description: 10-day TNS interventional protocol over an 10-day follow-up. Subjects will have electrodes (Superior Silver 1.25-in. diameter) placed on their foreheads to stimulate the V1 branches of the trigeminal nerve bilaterally for approximately 30 minutes each day. Current was adjusted to maintain comfortable but perceptible levels of stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trigeminal nerve stimulation
Description: 10-day TNS interventional protocol over an 10-day follow-up. Subjects will have electrodes (Superior Silver 1.25-in. diameter) placed on their foreheads to stimulate the V1 branches of the trigeminal nerve bilaterally for approximately 30 minutes each day. Current was adjusted to maintain comfortable but perceptible levels of stimulation
Study: NCT04637373

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Description: adding Hysteroscopy before and after suction curettage for early missed abortion to define the wall of implantation and look for retained products of conception
Study: NCT04554355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-based PA intervention
Description: Provide moderate to vigorous fun-game based exercises for adolescents with ID in schools to help them reduce obesity and improve fitness levels.
Study: NCT02687815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D3 4000 IU
Description: The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.
Study: NCT02384031

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traumatic needle
Description: Lumbar puncture is performed with a traumatic needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic needle
Description: Lumbar puncture is performed with an atraumatic needle
Study: NCT04149366

Intervention type: DEVICE
Intervention: Retainer
Description: Orthodontic retainer
Study: NCT02137473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human milk-based fortifier

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bovine protein-based fortifier
Study: NCT00452127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO131921
Description: Escalating doses by IV infusion
Study: NCT02777554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast IR
Description: Apremilast immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast IR
Description: Apremilast immediate release tablet
Study: NCT03343769

Intervention type: OTHER
Intervention: Measurement of maximal moment of the plantar flexor and dorsiflexor muscles
Description: 5-second repetitions

Intervention type: OTHER
Intervention: Measurement of the moment of the plantar flexors and dorsiflexors corresponding to RMS activity during balance measurements
Description: 3 10-second repetitions

Intervention type: OTHER
Intervention: Measurement of the moment of the plantar flexors and dorsiflexors corresponding to RMS activity during balance measurements
Description: 3 10-second repetitions
Study: NCT00376168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plant cell expressed recombinant glucocerebrosidase (prGCD)
Description: Intravenous infusion every two weeks for 9 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plant cell expressed recombinant glucocerebrosidase (prGCD)
Description: Intravenous infusion every 2 weeks for 9 months
Study: NCT03863613

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pessary
Description: A soft, flexible, silicone pessary (Arabin®, Dr Arabin GmbH \& Co KG, Germany) will be inserted through the vagina, upward around the cervix.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pessary
Description: A soft, flexible, silicone pessary (Arabin®, Dr Arabin GmbH \& Co KG, Germany) will be inserted through the vagina, upward around the cervix.
Study: NCT02777554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast IR
Description: Apremilast immediate release tablet
Study: NCT03863613

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical cerclage
Description: Cervical cerclage using Mc Donald technique, under anaesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical cerclage
Description: Cervical cerclage using Mc Donald technique, under anaesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal progesterone
Description: Cyclogest® 400mg, Actavis, United Kingdom, applied once daily at bedtime
Study: NCT02777554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast IR
Description: Apremilast immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast IR
Description: Apremilast immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast IR
Description: Apremilast immediate release tablet
Study: NCT03854903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Bosutinib is taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Bosutinib is taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Bosutinib is taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Bosutinib is taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant is given as an intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant is given as an intramuscular injection.
Study: NCT00515060

Intervention type: OTHER
Intervention: Sensory Tests
Description: Tests to find the threshold at which perceive stimuli.
Study: NCT01585597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zoll- Coolgaurd 3000
Description: Goal temperature of 33 degrees Centigrade for a duration of 12 hours and then actively rewarmed by 0.2 degrees Centigrade per hour.
Study: NCT03854903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant is given as an intramuscular injection.
Study: NCT03376919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLs++ gait training
Description: CLs++ gait training
Study: NCT02397512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: application of lactulose
Description: Subjects will ingest 50g of lactulose once

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: application of sucrose
Description: Subjects will ingest 50g of sucrose once
Study: NCT01960257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Health Feedback System
Description: This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their TB medications. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their TB medications.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SOC DOT
Study: NCT03035188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: 1 capsule (150 mg vismodegib) taken once daily for a maximum of 12 weeks.
Study: NCT02777554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast XL
Description: Apremilast extended release formulation tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast XL
Description: Apremilast extended release formulation tablet
Study: NCT02890173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Study: NCT00868920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient control of pump
Description: Patient controls sedation pump during colonoscopy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anesthesiologist controlled sedation
Description: Anesthesiologist will control the sedation pump during colonoscopy.